Hydroxychloroquine as a primary prophylactic agent against SARS-CoV-2 infection: A cohort study
Objective: Hydroxychloroquine has been proposed as a primary prophylactic agent against coronavirus disease 2019 (COVID-19). This study aimed to investigate if patients treated with hydroxychloroquine for a non-COVID-19 indication had a lower risk of verified infection with severe acute respiratory...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-07-01
|
| Series: | International Journal of Infectious Diseases |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1201971221004781 |
| _version_ | 1818621423442198528 |
|---|---|
| author | Peter Kamstrup Pradeesh Sivapalan Josefin Eklöf Nils Hoyer Charlotte Suppli Ulrik Lars Pedersen Therese S. Lapperre Zitta Barrella Harboe Uffe Bodtger Rasmus Dahlin Bojesen Kjell E.J. Håkansson Casper Tidemandsen Karin Armbruster Andrea Browatzki Howraman Meteran Christian Niels Meyer Kristoffer Grundtvig Skaarup Mats Christian Højbjerg Lassen Jens D. Lundgren Tor Biering-Sørensen Jens-Ulrik Jensen |
| author_facet | Peter Kamstrup Pradeesh Sivapalan Josefin Eklöf Nils Hoyer Charlotte Suppli Ulrik Lars Pedersen Therese S. Lapperre Zitta Barrella Harboe Uffe Bodtger Rasmus Dahlin Bojesen Kjell E.J. Håkansson Casper Tidemandsen Karin Armbruster Andrea Browatzki Howraman Meteran Christian Niels Meyer Kristoffer Grundtvig Skaarup Mats Christian Højbjerg Lassen Jens D. Lundgren Tor Biering-Sørensen Jens-Ulrik Jensen |
| author_sort | Peter Kamstrup |
| collection | DOAJ |
| description | Objective: Hydroxychloroquine has been proposed as a primary prophylactic agent against coronavirus disease 2019 (COVID-19). This study aimed to investigate if patients treated with hydroxychloroquine for a non-COVID-19 indication had a lower risk of verified infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) compared with matched controls. Methods: A cohort comprising all persons in Denmark collecting hydroxychloroquine prescriptions in 2020 and 2019 (i.e., both during and before SARS-CoV-2 was confirmed in Denmark), matched by age and sex with controls, was studied. Data were collected using the Danish national registries, which contain complete information on patient health data, prescriptions and microbiological test results. The main outcome was microbiologically verified SARS-CoV-2 infection. Results: In total, 5488 hydroxychloroquine users were matched with 54,486 non-users. At baseline, the groups differed in terms of diagnoses of pulmonary disease, cardiovascular disease, renal disease, gastrointestinal/metabolic disease and dementia, as well as treatment with antirheumatic drugs. The final model was adjusted for these potential confounders. Use of hydroxychloroquine for non-COVID-19 indications was not associated with any change in confirmed SARS-CoV-2 (hazard ratio 0.90, 95% confidence interval 0.76–1.07). This result was robust in the propensity-score-matched sensitivity analysis. Conclusion: This study, which is the largest to date to investigate the primary prophylactic effect of hydroxychloroquine against SARS-CoV-2, does not support any prophylactic benefit of hydroxychloroquine in the prevention of infection with SARS-CoV-2. |
| first_indexed | 2024-12-16T18:09:02Z |
| format | Article |
| id | doaj.art-6ea3e4eae5cb41fc95e75515211301d9 |
| institution | Directory Open Access Journal |
| issn | 1201-9712 |
| language | English |
| last_indexed | 2024-12-16T18:09:02Z |
| publishDate | 2021-07-01 |
| publisher | Elsevier |
| record_format | Article |
| series | International Journal of Infectious Diseases |
| spelling | doaj.art-6ea3e4eae5cb41fc95e75515211301d92022-12-21T22:21:50ZengElsevierInternational Journal of Infectious Diseases1201-97122021-07-01108370376Hydroxychloroquine as a primary prophylactic agent against SARS-CoV-2 infection: A cohort studyPeter Kamstrup0Pradeesh Sivapalan1Josefin Eklöf2Nils Hoyer3Charlotte Suppli Ulrik4Lars Pedersen5Therese S. Lapperre6Zitta Barrella Harboe7Uffe Bodtger8Rasmus Dahlin Bojesen9Kjell E.J. Håkansson10Casper Tidemandsen11Karin Armbruster12Andrea Browatzki13Howraman Meteran14Christian Niels Meyer15Kristoffer Grundtvig Skaarup16Mats Christian Højbjerg Lassen17Jens D. Lundgren18Tor Biering-Sørensen19Jens-Ulrik Jensen20Section of Respiratory Medicine, Department of Medicine, Copenhagen University Hospital Herlev and Gentofte Hospital, Hellerup, Denmark; Corresponding author at: Section of Respiratory Medicine, Department of Medicine, Herlev and Gentofte Hospital, University of Copenhagen, Gentofte Hospitalsvej 7, Ground Floor, DK-2900 Hellerup, Denmark.Section of Respiratory Medicine, Department of Medicine, Copenhagen University Hospital Herlev and Gentofte Hospital, Hellerup, DenmarkSection of Respiratory Medicine, Department of Medicine, Copenhagen University Hospital Herlev and Gentofte Hospital, Hellerup, DenmarkSection of Respiratory Medicine, Department of Medicine, Copenhagen University Hospital Herlev and Gentofte Hospital, Hellerup, DenmarkDepartment of Respiratory Medicine, Copenhagen University Hospital-Hvidovre, Hvidovre, DenmarkDepartment of Respiratory Medicine, Copenhagen University Hospital-Bispebjerg, Copenhagen, DenmarkDepartment of Respiratory Medicine, Copenhagen University Hospital-Bispebjerg, Copenhagen, DenmarkDepartment of Pulmonary and Infectious Diseases, Copenhagen University Hospital North Zealand, Hillerød, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, DenmarkRespiratory Research Unit, Department of Respiratory Medicine, Næstved, Slagelse and Ringsted Hospitals, Næstved, DenmarkDepartment of Surgery, Næstved, Slagelse and Ringsted Hospitals, Slagelse, DenmarkDepartment of Respiratory Medicine, Copenhagen University Hospital-Hvidovre, Hvidovre, DenmarkDepartment of Respiratory Medicine, Copenhagen University Hospital-Hvidovre, Hvidovre, DenmarkSection of Respiratory Medicine, Department of Medicine, Copenhagen University Hospital Herlev and Gentofte Hospital, Hellerup, DenmarkDepartment of Pulmonary and Infectious Diseases, Copenhagen University Hospital North Zealand, Hillerød, DenmarkSection of Respiratory Medicine, Department of Medicine, Copenhagen University Hospital Herlev and Gentofte Hospital, Hellerup, DenmarkDepartment of Medicine, Zealand University Hospital, Roskilde, DenmarkDepartment of Cardiology, Copenhagen University Hospital Herlev and Gentofte Hospital, Hellerup, DenmarkDepartment of Cardiology, Copenhagen University Hospital Herlev and Gentofte Hospital, Hellerup, DenmarkDepartment of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; PERSIMUNE & CHIP: Department of Infectious Diseases, Copenhagen University Hospital-Rigshospitalet, Copenhagen, DenmarkDepartment of Cardiology, Copenhagen University Hospital Herlev and Gentofte Hospital, Hellerup, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, DenmarkSection of Respiratory Medicine, Department of Medicine, Copenhagen University Hospital Herlev and Gentofte Hospital, Hellerup, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; PERSIMUNE & CHIP: Department of Infectious Diseases, Copenhagen University Hospital-Rigshospitalet, Copenhagen, DenmarkObjective: Hydroxychloroquine has been proposed as a primary prophylactic agent against coronavirus disease 2019 (COVID-19). This study aimed to investigate if patients treated with hydroxychloroquine for a non-COVID-19 indication had a lower risk of verified infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) compared with matched controls. Methods: A cohort comprising all persons in Denmark collecting hydroxychloroquine prescriptions in 2020 and 2019 (i.e., both during and before SARS-CoV-2 was confirmed in Denmark), matched by age and sex with controls, was studied. Data were collected using the Danish national registries, which contain complete information on patient health data, prescriptions and microbiological test results. The main outcome was microbiologically verified SARS-CoV-2 infection. Results: In total, 5488 hydroxychloroquine users were matched with 54,486 non-users. At baseline, the groups differed in terms of diagnoses of pulmonary disease, cardiovascular disease, renal disease, gastrointestinal/metabolic disease and dementia, as well as treatment with antirheumatic drugs. The final model was adjusted for these potential confounders. Use of hydroxychloroquine for non-COVID-19 indications was not associated with any change in confirmed SARS-CoV-2 (hazard ratio 0.90, 95% confidence interval 0.76–1.07). This result was robust in the propensity-score-matched sensitivity analysis. Conclusion: This study, which is the largest to date to investigate the primary prophylactic effect of hydroxychloroquine against SARS-CoV-2, does not support any prophylactic benefit of hydroxychloroquine in the prevention of infection with SARS-CoV-2.http://www.sciencedirect.com/science/article/pii/S1201971221004781HydroxychloroquineSARS-CoV-2COVID-19ProphylaxisEpidemiology |
| spellingShingle | Peter Kamstrup Pradeesh Sivapalan Josefin Eklöf Nils Hoyer Charlotte Suppli Ulrik Lars Pedersen Therese S. Lapperre Zitta Barrella Harboe Uffe Bodtger Rasmus Dahlin Bojesen Kjell E.J. Håkansson Casper Tidemandsen Karin Armbruster Andrea Browatzki Howraman Meteran Christian Niels Meyer Kristoffer Grundtvig Skaarup Mats Christian Højbjerg Lassen Jens D. Lundgren Tor Biering-Sørensen Jens-Ulrik Jensen Hydroxychloroquine as a primary prophylactic agent against SARS-CoV-2 infection: A cohort study International Journal of Infectious Diseases Hydroxychloroquine SARS-CoV-2 COVID-19 Prophylaxis Epidemiology |
| title | Hydroxychloroquine as a primary prophylactic agent against SARS-CoV-2 infection: A cohort study |
| title_full | Hydroxychloroquine as a primary prophylactic agent against SARS-CoV-2 infection: A cohort study |
| title_fullStr | Hydroxychloroquine as a primary prophylactic agent against SARS-CoV-2 infection: A cohort study |
| title_full_unstemmed | Hydroxychloroquine as a primary prophylactic agent against SARS-CoV-2 infection: A cohort study |
| title_short | Hydroxychloroquine as a primary prophylactic agent against SARS-CoV-2 infection: A cohort study |
| title_sort | hydroxychloroquine as a primary prophylactic agent against sars cov 2 infection a cohort study |
| topic | Hydroxychloroquine SARS-CoV-2 COVID-19 Prophylaxis Epidemiology |
| url | http://www.sciencedirect.com/science/article/pii/S1201971221004781 |
| work_keys_str_mv | AT peterkamstrup hydroxychloroquineasaprimaryprophylacticagentagainstsarscov2infectionacohortstudy AT pradeeshsivapalan hydroxychloroquineasaprimaryprophylacticagentagainstsarscov2infectionacohortstudy AT josefineklof hydroxychloroquineasaprimaryprophylacticagentagainstsarscov2infectionacohortstudy AT nilshoyer hydroxychloroquineasaprimaryprophylacticagentagainstsarscov2infectionacohortstudy AT charlottesuppliulrik hydroxychloroquineasaprimaryprophylacticagentagainstsarscov2infectionacohortstudy AT larspedersen hydroxychloroquineasaprimaryprophylacticagentagainstsarscov2infectionacohortstudy AT thereseslapperre hydroxychloroquineasaprimaryprophylacticagentagainstsarscov2infectionacohortstudy AT zittabarrellaharboe hydroxychloroquineasaprimaryprophylacticagentagainstsarscov2infectionacohortstudy AT uffebodtger hydroxychloroquineasaprimaryprophylacticagentagainstsarscov2infectionacohortstudy AT rasmusdahlinbojesen hydroxychloroquineasaprimaryprophylacticagentagainstsarscov2infectionacohortstudy AT kjellejhakansson hydroxychloroquineasaprimaryprophylacticagentagainstsarscov2infectionacohortstudy AT caspertidemandsen hydroxychloroquineasaprimaryprophylacticagentagainstsarscov2infectionacohortstudy AT karinarmbruster hydroxychloroquineasaprimaryprophylacticagentagainstsarscov2infectionacohortstudy AT andreabrowatzki hydroxychloroquineasaprimaryprophylacticagentagainstsarscov2infectionacohortstudy AT howramanmeteran hydroxychloroquineasaprimaryprophylacticagentagainstsarscov2infectionacohortstudy AT christiannielsmeyer hydroxychloroquineasaprimaryprophylacticagentagainstsarscov2infectionacohortstudy AT kristoffergrundtvigskaarup hydroxychloroquineasaprimaryprophylacticagentagainstsarscov2infectionacohortstudy AT matschristianhøjbjerglassen hydroxychloroquineasaprimaryprophylacticagentagainstsarscov2infectionacohortstudy AT jensdlundgren hydroxychloroquineasaprimaryprophylacticagentagainstsarscov2infectionacohortstudy AT torbieringsørensen hydroxychloroquineasaprimaryprophylacticagentagainstsarscov2infectionacohortstudy AT jensulrikjensen hydroxychloroquineasaprimaryprophylacticagentagainstsarscov2infectionacohortstudy |